ClinicalTrials.gg
CompletedNCT07082816Updated Apr 21, 2026

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

A Phase 3 interventional study of Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution and Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution in Ocular Hypertension and Open Angle Glaucoma, sponsored by Alcon Research. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
489
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
3rd of 17
489 · median 85
Started
2025
with 3 others
Phase 3
5 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Alcon Research

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 3rd largest by enrollment, is one of 4 that started in 2025, is one of 5 in phase 3, and was the 15th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Read the detailed description

About 470 adults with OAG or OHT will be randomly divided into 2 groups. One group will use the new Reformulated PG324 eye drops, and the other group will use the marketed PG324 eye drops. This study will be double-masked, so neither the researcher nor the participant will know which eye drop was administered. The expected individual duration of participation is approximately 3 months.

03

Conditions studied

  • Ocular Hypertension
  • Open Angle Glaucoma

Browse trials for

Keywords

  • Glaucoma
  • OAG
  • OHT
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 489 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of open-angle glaucoma or ocular hypertension in both eyes;
  • Unmedicated intraocular pressure measurements in the study eye as specified in the protocol;
  • Corrected distance visual acuity equal to or better than 20/100 in the study eye.

Key Exclusion Criteria:

  • Current use of more than 2 ocular hypotensive medications within 30 days;
  • Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening;
  • Use of topical ocular medication of any kind within 5 days of Screening or throughout the study with the exception of ocular hypotensive medications (must be washed out).
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
489 participants (actual)

Study arms

  • Experimental
    Reformulated PG324

    One drop of netarsudil 0.01%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months

    Drug: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution

  • Active comparator
    PG324

    One drop of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months

    Drug: Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution

Interventions

  • DrugNetarsudil 0.01%/latanoprost 0.005% ophthalmic solution

    Drug page: Netarsudil

    Investigational ophthalmic solution

    Also known as: Reformulated PG324

  • DrugNetarsudil 0.02%/latanoprost 0.005% ophthalmic solution

    Drug page: Netarsudil

    Commercially available ophthalmic solution

    Also known as: PG324, Rocklatan®

07

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure at each timepoint post-randomization

    Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint.

    Time frame: Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours

Secondary outcomes

  1. Proportion of subjects with moderate to severe conjunctival hyperemia as assessed by biomicroscopy

    The subject will undergo a slit lamp examination at all visits, except for dispensing visits. The presence of moderate to severe conjunctival hyperemia (redness) will be recorded.

    Time frame: Up to Month 3/study exit

  2. Proportion of subjects with conjunctival hyperemia adverse events

    Occurrences of conjunctival hyperemia (redness) adverse events, either subject or investigator reported, will be recorded at each visit.

    Time frame: Up to Month 3/study exit

  3. Mean change from diurnally adjusted baseline IOP at each timepoint post-randomization

    Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint. Change is defined as the follow-up (Week 2, Week 6, and Month 3) minus baseline (Day 1) at each timepoint.

    Time frame: Baseline (Day 1), Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours

  4. Percent change from diurnally adjusted baseline IOP at each timepoint post-randomization

    Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint. Change is defined as the follow-up (Week 2, Week 6, and Month 3) minus baseline (Day 1) at each timepoint.

    Time frame: Baseline (Day 1), Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours

  5. Mean TSS-IOP scores at Month 3

    The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) module is a 15-item questionnaire designed to assess subject satisfaction with ocular hypotensive medication(s). Subjects will respond to each item using a 5-, 6-, or 7-point Likert Scale. Individual scores will be computed by adding the scale values of items within a satisfaction category and transforming the resulting value into a score between 0 and 100. Higher scores are indicative of greater satisfaction. The questionnaire will be self-administered.

    Time frame: Month 3

  6. Mean Changes in TSS-IOP scores from Screening to Month 3

    The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) module is a 15-item questionnaire designed to assess subject satisfaction with ocular hypotensive medication(s). Subjects will respond to each item using a 5-, 6-, or 7-point Likert Scale. Individual scores will be computed by adding the scale values of items within a satisfaction category and transforming the resulting value into a score between 0 and 100. Higher scores are indicative of greater satisfaction. The questionnaire will be self-administered.

    Time frame: Month 3

08

Study locations

30 sites
  • Trinity Research Group
    Dothan, Alabama 36301, United States
  • Eye Doctors of Arizona
    Phoenix, Arizona 85028, United States
  • Orange County Ophthalmology Medical Group
    Garden Grove, California 92843, United States
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • Eye Research Foundation
    Newport Beach, California 92663, United States
  • North Bay Eye Associates
    Petaluma, California 94954, United States
  • Sacramento Eye Consultants
    Sacramento, California 95815, United States
  • Central Florida Eye Specialists
    DeLand, Florida 32720, United States
  • Glaucoma Specialists of South Florida
    Delray Beach, Florida 33484, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32256, United States
  • Central Florida Eye Associates
    Lakeland, Florida 33805, United States
  • The Eye Institute of West Florida
    Largo, Florida 33770, United States
  • Lee Shettle Eye
    Largo, Florida 33773, United States
  • North Georgia Eye Associates
    Gainesville, Georgia 30501, United States
  • Coastal Research Associates
    Roswell, Georgia 30076, United States
  • Kannarr Eye Care LLC
    Pittsburg, Kansas 66762, United States
  • NorthEast Eye Research Associates, LLC
    Westborough, Massachusetts 01581, United States
  • Coldwater Vision Research
    Coldwater, Mississippi 38618, United States
  • Las Vegas Eye Institute
    Henderson, Nevada 89052, United States
  • Rochester Ophthalmological Group
    Rochester, New York 14618, United States
  • Albemarle Eye Center
    Elizabeth City, North Carolina 27909, United States
  • Oculus Research, Inc.
    Garner, North Carolina 27529, United States
  • CORE, Inc.
    Shelby, North Carolina 28150, United States
  • Midwest Eye Center
    Cincinnati, Ohio 45236, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Scott & Christie and Associates, PC
    Cranberry Township, Pennsylvania 16066, United States
  • Southern College of Optometry
    Memphis, Tennessee 38104, United States
  • Total Eye Care, PA
    Memphis, Tennessee 38119, United States
  • The Eye Institute of Utah
    Salt Lake City, Utah 84107, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Apr 2026, 7 months.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 7 months is below that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 24, 2025
StartActual
Sep 2, 2025
Primary completionActual
Apr 6, 2026
CompletionActual
Apr 6, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07082816
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Sep 2, 2025
Primary completion
Apr 6, 2026
Completion
Apr 6, 2026
Last update
Apr 21, 2026

Study contacts

Clinical Trial Lead, Pharma
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion